company background image
VSTM logo

Verastem NasdaqCM:VSTM Stock Report

Last Price

US$11.82

Market Cap

US$299.0m

7D

0.3%

1Y

119.0%

Updated

27 Mar, 2024

Data

Company Financials +

VSTM Stock Overview

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States.

VSTM fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Verastem, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Verastem
Historical stock prices
Current Share PriceUS$11.82
52 Week HighUS$15.18
52 Week LowUS$4.20
Beta0.49
1 Month Change-9.70%
3 Month Change42.93%
1 Year Change118.99%
3 Year Change-60.12%
5 Year Change-67.81%
Change since IPO-91.12%

Recent News & Updates

Recent updates

Verastem: Moving Forward

Sep 13

Health Check: How Prudently Does Verastem (NASDAQ:VSTM) Use Debt?

Sep 01
Health Check: How Prudently Does Verastem (NASDAQ:VSTM) Use Debt?

Verastem Non-GAAP EPS of -$0.11 in-line

Aug 08

Verastem: Looking Increasingly Attractive

Jun 29

Verastem: Time To Take My Position Out Of Mothball

Apr 19

Vectoring In On Verastem

Jan 12

Verastem: Buying Opportunity Following Unjustified Sell-Off

Sep 22

Does Verastem (NASDAQ:VSTM) Have A Healthy Balance Sheet?

Jun 23
Does Verastem (NASDAQ:VSTM) Have A Healthy Balance Sheet?

Verastem to highlight potential of ovarian cancer therapy on upcoming investor event

May 26

Analysts Are Betting On Verastem, Inc. (NASDAQ:VSTM) With A Big Upgrade This Week

May 25
Analysts Are Betting On Verastem, Inc. (NASDAQ:VSTM) With A Big Upgrade This Week

Health Check: How Prudently Does Verastem (NASDAQ:VSTM) Use Debt?

Mar 02
Health Check: How Prudently Does Verastem (NASDAQ:VSTM) Use Debt?

What Is The Ownership Structure Like For Verastem, Inc. (NASDAQ:VSTM)?

Feb 02
What Is The Ownership Structure Like For Verastem, Inc. (NASDAQ:VSTM)?

Verastem Oncology: Targeting The RAS Pathway To Develop New Cancer Medicines

Jan 12

Verastem Oncology appoints chief medical officer

Jan 06

The Verastem (NASDAQ:VSTM) Share Price Is Up 68% And Shareholders Are Holding On

Jan 05
The Verastem (NASDAQ:VSTM) Share Price Is Up 68% And Shareholders Are Holding On

Shareholder Returns

VSTMUS BiotechsUS Market
7D0.3%0.9%0.4%
1Y119.0%10.3%28.8%

Return vs Industry: VSTM exceeded the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: VSTM exceeded the US Market which returned 29.5% over the past year.

Price Volatility

Is VSTM's price volatile compared to industry and market?
VSTM volatility
VSTM Average Weekly Movement9.9%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: VSTM's share price has been volatile over the past 3 months.

Volatility Over Time: VSTM's weekly volatility has decreased from 20% to 10% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201073Dan Patersonhttps://www.verastem.com

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205.

Verastem, Inc. Fundamentals Summary

How do Verastem's earnings and revenue compare to its market cap?
VSTM fundamental statistics
Market capUS$298.99m
Earnings (TTM)-US$87.37m
Revenue (TTM)n/a

0.0x

P/S Ratio

-3.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VSTM income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$87.37m
Earnings-US$87.37m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-3.45
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio56.4%

How did VSTM perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.